Cargando…

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer

SIMPLE SUMMARY: The mechanisms of intrinsic and acquired resistance to CDK4/6 inhibitors are poorly understood. Patients with HR+ MBC treated with CDK4/6i and antiestrogen therapy were grouped into early (<6 months), intermediate (6–24 months for 0–1 lines; 6–9 months for ≥2 lines), or late progr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jin Sun, Yost, Susan E., Li, Sierra Min, Cui, Yujie, Frankel, Paul H., Yuan, Yate-Ching, Schmolze, Daniel, Egelston, Colt A., Guo, Weihua, Murga, Mireya, Chang, Helen, Bosserman, Linda, Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264913/ https://www.ncbi.nlm.nih.gov/pubmed/35804935 http://dx.doi.org/10.3390/cancers14133159

Ejemplares similares

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2022)

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study
por: Yuan, Yuan, et al.
Publicado: (2023)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
por: Lee, Jin Sun, et al.
Publicado: (2023)

Tumor-infiltrating exhausted CD8(+) T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer
por: Egelston, Colt A., et al.
Publicado: (2022)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses
por: Kumbhari, Adarsh, et al.
Publicado: (2020)

Kinesin Family Member C1 (KIFC1/HSET) Underlies Aggressive Disease in Androgen Receptor-Low and Basal-Like Triple-Negative Breast Cancers
por: Jinna, Nikita, et al.
Publicado: (2023)

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival
por: Afkhami, Michelle, et al.
Publicado: (2019)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Hepatotoxicity After CDK 4/6 Inhibitor Initiation in the Treatment of Hormone-Positive Metastatic Breast Cancer
por: Wani, Kashmira, et al.
Publicado: (2023)

Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases
por: Ye, Jian, et al.
Publicado: (2023)

Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes
por: McQuerry, Jasmine A., et al.
Publicado: (2019)

Reprogramming of PD-1(+) M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma
por: Han, Zhen, et al.
Publicado: (2023)

Metformin and ICG-001 Act Synergistically to Abrogate Cancer Stem Cells-Mediated Chemoresistance in Colorectal Cancer by Promoting Apoptosis and Autophagy
por: Roy, Souvick, et al.
Publicado: (2022)

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
por: Khorrami, Mohammadhadi, et al.
Publicado: (2023)

Prospective Comparison of Medical Oncologists and a Machine Learning Model to Predict 3-Month Mortality in Patients With Metastatic Solid Tumors
por: Zachariah, Finly J., et al.
Publicado: (2022)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

BD-Func: a streamlined algorithm for predicting activation and inhibition of pathways
por: Warden, Charles D., et al.
Publicado: (2013)

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints
por: Angyal, Adrienn, et al.
Publicado: (2010)

De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer
por: Wu, Xiwei, et al.
Publicado: (2012)

Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer
por: Guan, Min, et al.
Publicado: (2015)

Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus
por: Papageorgiou, Christos, et al.
Publicado: (2021)

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Corrigendum: Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report
por: Li, Ke-Hao, et al.
Publicado: (2022)

Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival
por: Chao, Joseph, et al.
Publicado: (2020)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
por: Mittal, Abhenil, et al.
Publicado: (2023)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u47to3aj8nvod99g7ascq227m9